why are glp-1 drugs expensive National Academy of Medicine | medications changing the conversation about obesity, but what does the evidence really say? like Ozempic, Wegovy, and How to Afford GLP-1s in

Keep out of reach of children under 18

Pfizer has said it expects pills to eventually capture about a third of the obesity drug market, which is predicted to grow to about $130 billion by the end of the decade.

not using GLP-1 receptor agonists had significantly lower relative risks for mortality and respiratory failure, according to a presentation at the CHEST Annual Meeting.In a retrospective study, Saud Alawad, MBBS, third-year internal medicine resident at West Virginia University, and colleagues analyzed adults with a group 1 PAH

A variety of fixed combinations of 2 agents are available in the US and in many other countries

GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy